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Abstract: In the late 1960s, Barbaro and Zvaifler described a substance that caused antigen induced
histamine release from rabbit platelets producing antibodies in passive cutaneous anaphylaxis.
Henson described a ‘soluble factor’ released from leukocytes that induced vasoactive amine release in
platelets. Later observations by Siraganuan and Osler observed the existence of a diluted substance
that had the capacity to cause platelet activation. In 1972, the term platelet-activating factor (PAF)
was coined by Benveniste, Henson, and Cochrane. The structure of PAF was later elucidated by
Demopoulos, Pinckard, and Hanahan in 1979. These studies introduced the research world to PAF,
which is now recognised as a potent phospholipid mediator. Since its introduction to the literature,
research on PAF has grown due to interest in its vital cell signalling functions and more sinisterly its
role as a pro-inflammatory molecule in several chronic diseases including cardiovascular disease and
cancer. As it is forty years since the structural elucidation of PAF, the aim of this review is to provide
a historical account of the discovery of PAF and to provide a general overview of current and future
perspectives on PAF research in physiology and pathophysiology.
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1. Platelet-Activating Factor
Since its discovery, the structure of platelet-activating factor (PAF) also known as PAF-acether or
AGEPC (acetyl-glyceryl-ether-phosphorylcholine) has been identified as a phosphoglycerylether lipid
mediator involved in diverse physiological and pathophysiological processes. It seems apparent that
PAF has different physiological roles in animals, plants, and monocellular organisms. It is considered
the most potent lipid mediator known to date [1,2]. Previous to the 1970s, lipid mediators were thought
to be generally derived from phospholipids. However, PAF was the first intact phospholipid mediator
to demonstrate autacoid or messenger functions [3]. PAF was initially considered one molecule, which
is commonly referred to as the classical PAF. Now it is understood that there are a large number of
structurally related phospholipids or PAF analogues that are dissimilar in structure to PAF that interact
with the PAF-receptor (PAF-R) and belong to the ‘PAF family’, collectively known as PAF-like lipids
(PAFLL). However, for the purpose of this review, PAF refers to the classical structure reported in 1979,
which is responsible for most of the known biological effects and is thought to be the most potent PAF
molecule. PAF mediates a wide variety of cellular functions and cell–cell interactions. Therefore, PAF
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is involved in several physiological processes including apoptosis, physiological inflammation, wound
healing, reproduction, angiogenesis, long-term potentiation, and potentially retrograde signalling [4–7].
However, PAF is also a potent pro-inflammatory mediator that is implicated in a variety of conditions
and chronic diseases such as cancer, renal diseases, cerebrovascular and central nervous system
disorders, allergies, asthma, infections, and cardiovascular diseases (CVD) [5,8–13]. PAF is known to
carry out its broad pathophysiological actions at concentrations as low as 10−12 M and almost always by
10−9M as an intercellular messenger [14]. In evolutionary terms, many ether lipids were replaced over
time by their esterified analogues; however, PAF and other minor phosphoglycerylether molecules
were conserved in various organisms due to their important biological roles [15]. Hence, the importance
of understanding the role of PAF in various biological processes. The aim of this review is to provide a
historical account on the discovery of PAF, the research conducted since, and to provide future research
perspectives on PAF research in general.
2. The Discovery and Structural Elucidation of the Platelet-Activating Factor
2.1. The Discovery of the Platelet-Activating Factor
PAF was first introduced into the literature in 1966 when Barbaro and Zvaifler described a
substance that caused antigen induced histamine release from rabbit platelets producing antibodies
in passive cutaneous anaphylaxis [16]. Almost four years later, Henson described a ‘soluble factor’
released from leukocytes that induced vasoactive amine release in platelets. Further observations
by Siraganuan and Osler [17] described the existence of a diluted substance that had the capacity to
cause platelet activation. A year later Jacques Benveniste and colleagues elaborated on the findings
of the previous two studies and described a novel factor that induced aggregation and secretion of
platelets, which participated in a leukocyte-dependent histamine release from rabbit platelets [18].
Hence, the term platelet-activating factor (PAF) was coined because of the initial observations of its
effects on platelets [18]. It was later discerned that PAF was a lipid-like molecule [19]. It is recalled
that to study PAF Benveniste prepared a measure of PAF from 100 L of hog blood, which resulted in a
100 L solution from which 1 µL was sufficient to induce platelet aggregation, indicating its high level
of potency [20]. However, this amount of PAF was too low to use techniques at the time such as mass
spectrometry or magnetic resonance that might determine the structure of the bioactive compound [20].
Despite the lack of structural data, Benveniste and others had determined several of the physical
characteristics of PAF. They determined that it was a lipid compound, it could bind to albumin,
and it migrated between lysolecithin and sphingomyelin in thin-layer chromatography separation,
all properties of which were similar to that of lysophosphatidylcholine. The compound was also
affected by several phospholipases (PLA2, PLC, and PLD) but resistant to others (sphingomyelinase C
and PLA1), indicating that indeed it had a phospholipid type structure [20,21]. Studies began to discern
that PAF was implicated in IgE anaphylaxis [22] and many of the properties of PAF released during
IgE anaphylaxis began to be elucidated [23]. Furthermore, the role of PAF in platelet aggregation was
beginning to be further understood by June 1979 [24].
2.2. Structural Elucidation of the Platelet-Activating Factor
Following several experiments with phospholipases, etc. the structure of PAF was thought
to be 2-acyl-sn-glycero-3-phosphocholine (1-lysophosphatidylcholine) [25], but owing to acyl chain
migration this molecule was known for its instability and did not demonstrate the biological properties
corresponding to PAF [20,26]. Around that time, several other structures were interrogated, and many
researchers were involved in discussions as reviewed by Chap [20]. However, on the 10th of October
1979, Constantinos Demopoulos, Neal Pinckard, and Donald Hanahan, from San Antonio Texas
published the structure of PAF (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) under the name
AcGEPC (Acetyl-glyceryl-ether-phosphocholine), which was shown to have biological activities
indistinguishable from that of naturally generated rabbit PAF (Figure 1) [27]. The researchers
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realised that the AcGEPC they synthesised was indeed the same structure as naturally occurring
PAF. Interestingly, nineteen days after the Demopoulos, Pinckard, and Hanahan [27] publication,
the same structure was reported by a group led by Fred Snyder who were assessing the properties
of an isolated compound in the kidney that was responsible for peculiar biological activity, which
was known by them as the antihypertensive polar renomedullary lipid (APRL) [28]. These studies
were followed by an article by Benveniste who subsequently proposed the name PAF-acether [29].
Later articles confirmed that synthetically produced PAF initiated identical biological effects to the PAF
molecules responsible for IgE-induced systemic anaphylaxis [30], which also caused similar vascular,
cardiovascular, and respiratory problems associated with anaphylaxis in rabbits [31] and baboons [32].
In addition, platelets were not required to induce anaphylactic shock in rabbits when injected with
synthetic PAF, indicating for the first time that PAF acts via a receptor [33].
Hanahan and colleagues formally confirmed the structure of PAF in 1980 using mass spectrometry
and simplified their abbreviation of the molecules name to AGEPC [34]. Likewise, Benveniste and
colleagues simplified the name of the PAF precursor to lyso-PAF [35]. As many researchers were
working with PAF at the same time, it is reported that there were conflicting attitudes between the
groups with reference to what the name of the molecule should be. Furthermore, Chap described the
difficulty encountered by Benveniste who was unfortunate not to have elucidated the structure of PAF
previous to the other groups [20]. Considering that we now know PAF exhibits a vast diversity of
actions and the fact that a myriad of other molecules can activate platelets, it seems ironic that the
name PAF is a misnomer [36] that has remained in the literature.
However, that was not the end of Benveniste’s role in determining some of the properties of
PAF. Indeed, Benveniste and colleagues provided the first evidence that platelets synthesise PAF [37]
and they determined the subcellular localisation of PAF biosynthesis in human neutrophils [38].
However, Benveniste’s important role in the discovery of PAF may be overshadowed by his later
controversial research that led to major scientific scandals [20,39,40] that are not the subject of this
review. The very first account of the discovery of PAF and its various properties was published in
Nature in 1980 by Cusack [41]. The intensive and dedicated research of many scientists involved in the
discovery and structural elucidation of PAF in the 70s and 80s set in motion a research field that is ever
growing to this day, which has had profound implications to medical research.
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3. The Importance of Platelet-Activating Factor Research
PAF is implicated in various physiological processes and a multitude of pathophysiological
processes, as will be further discussed in Sections 3.1 and 3.2. However, the critical feature of PAF
physiologically and in disease is that the biological effects of PAF can be modulated by diet, lifestyle,
and environmental factors [5,43–46]. This means that PAF could be a potential therapeutic target for
many chronic diseases [5,8,10] and thus PAF is of significant importance and value to researchers
across several disciplines. Sections 3.1 and 3.2 discuss some of the main biological consequences
of PAF signalling in physiology and pathophysiology. While this review discusses many of these
events, not all of PAF’s roles are discussed due to the vast accumulation of research published around
PAF in the last forty years. In the last two years alone there has been over 2000 articles published in
relation to PAF. This review specifically focuses on some of the emerging PAF-related research trends
over the last decade. In particular, this article discusses the most contentious issues of PAF research
such as the role of the PAF metabolic enzymes in physiological and inflammatory processes and the
role of PAF in various chronic diseases, such as disorders of the central nervous system (CNS), CVD,
and cancer. These diseases have major health implications for patients and are an enormous burden to
healthcare globally. Indeed, some of the research highlighted in this article may lead to ground-breaking
discoveries that enhance our understanding of cell signalling, inflammation, and disease.
After the elucidation of the structure of PAF in 1979, there was much motivation in the development
of research in the field that from 1983 lead to several congresses being organised entirely focused on PAF
research. These congresses were held every three years worldwide until 2004 (Table 1). After 21 years,
PAF research became interdisciplinary and grew and expanded to virtually all areas of biochemistry
and medicine. The congresses stopped being organised as much of the research surrounding PAF were
disseminated at various international conferences. However, attempts have been made to reignite these
congresses as recent as February 2015 in Tokyo Japan, where PAF communications were presented in
special sessions at the ‘6th International Conference on Phospholipase A2 and Lipid Mediators’ [47].
Table 1. International conferences of platelet-activating factor (PAF).
Title Date Location
1st International Symposium on Platelet-Activating
Factor and Structurally Related Ether-Lipids 26–29 June 1983 Paris, France
2nd International Conference on Platelet-Activating
Factor and Structurally Related Ether-Lipids 26–29 October 1986 Gatlinburg, Tennessee, USA
3rd International Conference on Platelet-Activating
Factor and Structurally Related Ether-Lipids 8–12 May 1989 Tokyo, Japan
4th International Congress on Platelet-Activating
Factor and Related Lipid Mediators 22–25 September 1992 Snowbird, Utah, USA
5th International Congress on Platelet-Activating
Factor and Related Lipid Mediators 12–16 September 1995 Berlin, Germany
6th International Congress on Platelet-Activating
Factor and Related Lipid Mediators 21–24 September 1998 New Orleans, Louisiana, USA
7th International Congress on Platelet-Activating
Factor and Related Lipid Mediators 24–27 September 2001 Tokyo, Japan
8th International Congress on Platelet-Activating
Factor and Related Lipid Mediators 6–9 October 2004 Berlin, Germany
6th International Conference on Phospholipase A2
and Lipid Mediators 10–12 February 2015 Tokyo, Japan
3.1. PAF Signalling in Physiology
PAF was initially thought to be a single molecule, but as aforementioned, it became clear that
there were other structurally related phospholipids or PAFLL [14]. These molecules have semi-similar
or non-similar structures and exhibit similar biological activities to PAF [48]. PAF and PAFLL are
structurally defined ligands of the PAF-R, which has restricted expression on specific target cells of
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the immune, haemostatic, and inflammatory systems [12]. PAF itself is synthesised constitutively or
under appropriate stimuli by a variety of cells such as platelets, macrophages, monocytes, neutrophils,
basophils, eosinophils, mast cells, and endothelial cells [49]. PAF is synthesised by two markedly
different pathways known as the de novo and remodelling pathways. Fred Snyder aforementioned was
instrumental to the discovery of the anabolic and catabolic enzymes of PAF metabolism [50]. His research
group was responsible for discovering the roles of lyso-PAF acetyltransferase (Lyso-PAF-AT) as the main
regulatory enzyme of the remodelling pathway [51], PAF acetylhydrolase as the main regulatory enzyme
of PAF catabolism [52], a novel DTT (dithiothreitol)-insensitive CDP-choline phosphotransferase as
the main regulatory enzyme of the de novo pathway [53], and other enzymes implicated in PAF
metabolism [50]. It was thought that the remodelling enzymatic pathway of PAF biosynthesis was
responsible for the pro-inflammatory production of PAF in acute and chronic inflammation.
On the other hand, the de novo pathway was initially thought to be responsible for the constitutive
production of PAF, maintaining basal PAF levels. As a result, the de novo pathway was neglected
with regard to research in inflammation. However, it is now recognised that PAF-CPT, a key enzyme
of the de novo pathway, seems to be more active during chronic inflammatory manifestations [54].
Consequently, there is an increase in the basal levels of PAF related to the continuous activation of
inflammatory cascades during the development of inflammation-related chronic disorders [54–57];
hence the regulation of the biosynthetic pathways of PAF seem to be more complicated than previously
envisaged. PAF biosynthesis is correlated with well-established inflammatory and immunological
biomarkers of inflammation in various chronic disorders [8,56–60]. Nevertheless, the role of these
enzymes and others in PAF metabolism and disease is the subject of intensive research by a few
research groups, which have previously been reviewed [5,61–66]. There is considerable debate over
PAF-acetylhydrolase (PAF-AH), which is a catabolic enzyme of PAF; however, it may play a role in in
the development of atherosclerosis [65], which is elaborated on in Section 5.3. PAF-AH inactivates PAF
by removing the acetyl-group at the sn-2 position, which is a key feature of the regulation of circulating
PAF levels [8]. The actions and roles of the various metabolic enzymes of PAF are summarised in
Figure 2.
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as it is necessary for the day-to-day protection of tissue from pathogenic insults. PAF can mediate
events in a juxtacrine, paracrine, autocrine, and endocrine manner. In acute inflammation, PAF is
synthesised by endothelial cells stimulated with thrombin or other inflammatory mediators. This PAF
then activates polymorphonuclear leukocytes (PMNs), which are the first leukocyte responders and
key effectors cells of the acute inflammatory response to accumulate at an inflamed site [3,67,68].
These events were the first evidence of synthesis of a signalling factor for PMNs by inflamed endothelial
cells mediated by activation-dependent alterations in the affinity and avidity of β2 integrins on the
surface, which established that there was a molecular mechanism for the activation leukocytes at the
endothelial cell surface, rather than relying on the diffusion of chemotactic factors into the blood [3,69].
This led to further research demonstrating that PAF can induce a myriad of effects in PMNs and other
leukocytes, such as monocytes, whereby PAF is involved in NF-κB translocation and alterations of
gene expression [70]. Many of these signalling cascades and complex interactions are reviewed by
Prescott, Zimmerman, Stafforini, and McIntyre [3].
Apart from acute inflammation, PAF is involved in cell signalling mechanisms for a number
of other physiological processes. For instance, PAF has several surprising roles in reproduction
physiology. Indeed, PAF signalling modulates female reproductive events including ovulation,
fertilisation, preimplantation, implantation, and parturition. It is also thought that PAF plays a role in
male reproduction due to the presence of PAF in spermatozoa, which may be involved in the induction
of acrosome reaction and sperm motility [71–76].
Phospholipids predominate in the brain and play several critical structural and physiological
roles [77]. Therefore, it is unsurprising that PAF also seems to play a crucial role in cell signalling of
the CNS. PAF is synthesised by neural cells spontaneously or following appropriate stimuli [78,79]
and the presence of the PAF-R in brain membranes has been reported since 1988 [80]. Neuronal PAF
actions are associated with signal signalling processes mediated by phospholipase C (PLC) and
protein kinase C (PKC) [81]. PAF activity in the brain is not limited to its proinflammatory function,
neurotoxicity, and apoptosis [82], but it is also associated with neurotrophic effects [78]. Most notably,
the PAF-R is present on intracellular membranes and in the synaptic membranes of the cerebral cortex.
Indeed, it has been established that there is a relationship between PAF and the glutamate receptor in
the CNS [4,83,84]. Therefore, it is clear that PAF is a critical mediator in CNS physiology. However, PAF
may also be involved in CNS pathology, which warrants further research.
PAF is also a mediator of regular cardiovascular-related physiology as it involved in the mediation
of blood pressure and normal inflammatory and haemostatic responses [85–87]. Hence why the term
‘platelet-activating factor’ was coined. However, PAF is mostly known for its role in inflammatory
cascades that lead to the development of chronic diseases such as CVD and cancer, which are discussed
in Section 3.2.
3.2. PAF Signalling in Pathophysiology
It is well-known that PAF is involved in a wide range of inflammation-related conditions
and diseases [85]. As CVD is still the leading cause of global mortality [88], determining the
causes and how to prevent CVD is imperative and a major objective of modern medicine [45].
Systemic inflammation mediates all stages of atherosclerosis [89] in which PAF is a key inflammatory
mediator [5,10,11]. Several inflammatory mediators facilitate an interplay and crosstalk between
various cells and endothelial cells, which initiate inflammatory cascades that eventually results in
endothelial dysfunction and initiation of proatherogenic events [5,90]. PAF is one of the critical
junctions between several inflammatory pathways (cytokines, oxidative stress, eicosanoids, etc.) that
modulated the interplay between various cells participating in atherosclerosis [5]. PAF is synthesised
by many of the key cells (when activated) involved in the atherosclerotic process, including endothelial
cells, macrophages, monocytes, platelets, and even foam cells. Consequently, PAF is implicated in the
initiation of atherosclerosis and continues to be involved through plaque formation, development,
erosion, and rupture [5,10,11,91,92]. PAF levels can be increased by upstream mediators (IL-1β,
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IL-6, TNF-α, PAF itself, etc.) and in itself induce the production of downstream mediators [5].
In 2003, Demopoulos et al. [10] proposed that PAF is the molecular link between several theories
of atherosclerosis development due to the fact that many of the atherogenic properties of oxidised
low-density lipoproteins (LDL) can be attributed to the activity of PAF and PAFLL. PAF was termed ‘the
missing link’ that orchestrates thrombosis, inflammation, and oxidation responsible for atherogenesis.
As a result of decreased PAF-AH activity and a deficiency of endogenous or ingested antioxidants,
blood PAF levels can increase in inflammatory situations and during oxidative stress by peroxidation
of phospholipid cellular membranes and LDL oxidation [10]. Notably, it has been demonstrated that
endogenous or ingested PAF inhibitors can inhibit the actions of PAF [10,93]. However, the absence of
circulating antagonists may result in increased PAF activity [5]. Research relating to PAF antagonists
will be further explored in Section 4.
PAF and PAFLL can induce the release of reactive oxygen species (ROS) [10,94,95] that can lead
to LDL oxidation [96]. Likewise, LDL oxidation is responsible for an increase in PAF levels [97] and
oxidised LDL contains PAFLL [98]. This is significant as low concentrations of intact oxidised LDL
have the ability to activate platelets through a mechanism mediated by PAFLL and the PAF-R [99].
Juxtaposed, it seems that PAF-AH in high-density lipoproteins (HDL) protects against the activity
and production of oxidised LDL by hydrolysing PAF and PAFLL, thus reducing atherogenic changes
in LDL and related inflammatory processes [10,100–102]. However, it was also demonstrated that
upon LDL oxidation PAF-AH is gradually inactivated [97] potentially by oxygen radicals [103], thereby
hindering its ability to suppress the proinflammatory activities of PAF and PAFLL [97]. It is clear that
since Demopoulos’ et al. [10] hypothesised that PAF is the molecular link between atherosclerosis
theories, there has been a series of reviews arguing that PAF is a central mediator in cardiovascular
inflammation [5,11,104,105]. However, further research is still required to fully establish the role PAF
and its related metabolic enzymes in atherosclerosis and CVD in order to develop effective preventative
and therapeutic strategies.
Systemic inflammation is also the underlying cause and driving process accountable for several
other chronic diseases including cancer of which PAF and its receptor plays a significant role [8,106].
Apart from inducing inflammatory signalling, PAF also plays a significant role in suppressing the
immune system, promoting metastasis, and supporting tumour growth by altering local cytokine
and angiogenic networks [8,107,108]. Indeed, PAF is responsible for the activation of the NF-κB
pathways, PAF overexpression in various tumours, and promotion of inflammation and angiogenesis
in the tumour microenvironment [8,108–110]. There are several studies indicating that PAF and its
receptor are critical components of the molecular processes in the development and progression
of breast cancer [111,112], colorectal cancer [113], oesophageal cancer [58], lung cancer [59], liver
cancer [60], pancreatic cancers [114], skin cancers [115], and various other cancers [8,107]. This has
led to significant interest among researchers to develop novel therapeutics relating to PAF and
its metabolism [8,116]. As aforementioned, PAF seems to be critical in cell signalling in the CNS.
Therefore, it is unsurprising that PAF is also involved in the development of neurological and
neurodegenerative disorders such as Alzheimer’s disease and potentially Parkinson’s diseases [117].
Indeed, PAF is also a well-established mediator in a plethora of other inflammation-related diseases
including allergies [118,119] and anaphylaxis [12,19,120], HIV [55,121], sepsis [12,122], chronic
obstructive pulmonary disease (COPD) [123,124], bacterial [125–127] and viral infections [128], lung
pathology relating to smoking [123], asthma [129,130], periodontitis [131], and renal disorders [132].
A simplified example of PAF-induced pro-inflammatory cell signalling is outlined in Figure 3.
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Figure 3. A simplified schematic that illustrates the main pro-inflammatory signalling pathways that
PAF induces through binding with its receptor under certain stresses or stimuli in various pathways
and inflammatory cascades in inflammation-related chronic disorders.
The PAF-R is expressed on the membranes of several cell types that are central to physiological
and pathophysiological responses such as platelets, endothelial cells, monocytes, and macrophages.
Several risk factors can increase the synthesis of PAF and PAFLL and upregulate the expression of
the PAF-R. Activation of PAF-R signalling through Gq-linked mechanisms initiates PLCβ-mediated
hydrolysis of PIP2 leading to the formation of DAG and IP3 and subsequently to a transient increase of
CA2+ released from intracellular stores and the activation of PKC. The rise in Ca2+ activates cPLA2α
that leads to the release of lysophosphatides and AA that can be used as a substrate for the further
synthesis of PAF and eicosanoids respectively. The activation of cPLA2 and the PAF biosynthetic
enzymes (LPCAT) leads to additional synthesis of PAF and secondary lipid messengers. This results in
the occurrence of a PAF cycle that further amplifies the initial inflammatory response and leads to
the expression of pro-inflammatory genes that gives rise to the synthesis and release of various lipid
mediators, cytokines, growth factors, ROS, reactive nitrogenous species (RNS), and the expression of
integrins and selectins in the membranes of activated cells at the site of inflammation. Therefore, a rise
in the levels of downstream mediators, PAF, and the subsequent further activation of the PAF/PAF-R
pathways promotes the activation and aggregation of platelets and leukocytes, the activation of
endothelial cells, increased leukocyte adherence, motility, chemotaxis, invasion, and migration.
These processes culminate in the development of endothelial dysfunction, thus stimulating the onset
and development of inflammation-related chronic diseases and disorders. Juxtaposed, PAF-R induced
signalling through Gi-linked mechanisms inhibits the conversion of ATP to cAMP via adenylyl
cyclase, thus preventing the activation of PKA and related anti-inflammatory signalling processes.
Adapted with permission [5]. Abbreviations: AA, arachidonic acid; AC, adenylyl cyclase; AKT, protein
kinase B; ATP, adenosine triphosphate; Ca, calcium; cAMP, cyclic adenosine monophosphate; cPLA2,
cytosolic phospholipase A2; DAG, diacylglycerol; ERK, extracellular signal-regulated kinases; IL,
interleukin; LPCAT, lysophosphatidylcholine acyltransferase; Lyso-PC, lyso-phosphatidylcholine;
NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; MAPK, mitogen-activated
protein kinase; PAF, platelet-activating factor; PAFLL, PAF-like lipids; PAF-R, PAF-receptor; PI3K,
phosphatidylinositol 3-kinase; PIP2, phosphatidylinositol 4,5-bisphosphate; PKA, protein kinase A;
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PKC, protein kinase C; PLCβ, phospholipase C-β; mTOR, mechanistic target of rapamycin; RNS,
reactive nitrogenous species; ROS, reactive oxygen species; TNF-α, tumour necrosis factor-α.
4. The Potential Use of Platelet-Activating Factor Inhibitors as Therapeutics and Preventatives
of Disease
Research into potential physiological and therapeutic ways of suppressing PAF activity
demonstrated that endogenous or ingested PAF inhibitors could inhibit the actions of PAF [10,93].
Endogenous inhibitors of PAF have been identified in humans [133], many of which were identified
as cardiolipins [134,135]. As a consequence of discovering that the body circulated PAF antagonists,
it was thought that the absence of circulating antagonists could result in increased PAF activity [5].
Therefore, the potential role of PAF inhibitors in disease prevention and treatment has been of
significant interest over the last three decades. Initial indications in the early 1980s demonstrated
that PAF release from leukocytes could be modulated pharmacologically [136]. This was followed by
studies using pharmacological compounds such as ticlopidine and calmodulin to study PAF-induced
platelet aggregation [137,138]. At that time it was also shown that methanolic extracts of garlic bulbs
exhibited inhibition of various platelet agonists including PAF [139]. This seems to be the first time in
the literature that compounds originating from food were reported to have inhibited PAF-induced
platelet aggregation. This was a significant finding as it demonstrated the existence of not only
pharmacological therapeutics, but potentially dietary sources of PAF inhibitors also.
Around this period of PAF research there was a large increase in the number of published research
relating to the discovery of PAF antagonists of natural and synthetic origin for which we now know
of several hundred natural and synthetic PAF inhibitor molecules in existence [14]. In particular,
researchers were investigating the potential use of compounds known as ginkgolides isolated from the
Ginkgo biloba tree; a tree native to China, the existence of which dates back over 270 million years [140].
There are several ways to classify PAF inhibitors including if they are of natural of synthetic
origin, they can be classified by their various chemical structures, and they can be classified by
their interaction with the PAF-R, e.g., specific and non-specific inhibitors [141]. In terms of their
structures, PAF inhibitors can be PAF analogues such as polar lipids, or there are molecules that are
dihydropyridines, nitrogen heterocyclic compounds, phenolics, and other various natural medicinal
compounds [141–143].
Along with being classified into compounds of natural or synthetic origin, PAF inhibitors can be
characterised into two main classes according to their specificity: non-specific and specific inhibitors.
Non-specific PAF inhibitors are compounds that inhibit certain processes in the PAF-induced signal
transduction pathways such as calcium channel blockers, G-protein inhibitors, intracellular calcium
chelators, etc. [14]. Various non-specific PAF inhibitors were crucial to identifying the individual steps of
PAF-related signal transduction pathways. However, their pharmacological value is limited due to their
low specificity [144–147]. By contrast, specific PAF inhibitors competitively or noncompetitively bind
with the PAF-R. These types of inhibitors may have potential therapeutic value [5,14]. In Sections 4.1
and 4.2 some of the most important natural and synthetic inhibitors and their specificity are discussed.
4.1. PAF Inhibitors of Synthetic Origin
The initial synthetic PAF inhibitor compounds such as CV-3988 [148,149], CV-6209 [150], RO
19-3704 [151], and ONO-6240 [152] were structurally similar to PAF. In fact CV-3988 a thiazolium
derivative was a zwitterionic species that was the first synthetic antagonist of the PAF-R [148].
Later inhibitors replaced the glycerol backbone with cyclic structures such as SRI 63-441 [153],
SRI 63-073 [154], UR-11353 [155], and CL-184,005 [156]. Subsequently, other PAF antagonists
were developed that had no structural similarity to PAF. These antagonists were composed of
heterocyclic structures that were characterised by sp2 nitrogen atom that interacted with the
PAF-R as a hydrogen bond acceptor [141]. Many of these were derivatives of imidazolyl that
lead to the development of lexipafant [157] and modipafant [158], thiazolidine derivatives such
Molecules 2019, 24, 4414 10 of 32
as SM-10661 [159], pyrrolothiazole-related antagonists such as tulopafant [160], and hetrazepine
derivatives like WEB-2086 and WEB-2170 [161]. There are a plethora of synthetic PAF-R antagonists
including psychotropic triazolobenzodiazepines [162], L-652,731 [163], and various examples of
inorganic metal complexes [143,164]. However, it was later discovered that some of these antagonists
were not orally active and some had toxicity issues [165,166], thus they had limited therapeutic
value [167].
Clinical trials were conducted for several of these inhibitors, which demonstrated their tolerability
and safety, but there were issues with their efficacy; juxtaposed, there were several trials that indicated
positive outcomes following PAF-R antagonism. The inhibitors and their target diseases or disorders
are outlined in Table 2.
Table 2. A list of some of the major synthetic PAF antagonists assessed against several conditions in
clinical trials.
PAF-R
Antagonist Target Disease or Disorder Outcome Reference
Lexipafant
Cognitive impairment
complications as a result of
coronary artery bypass graft
No significant reduction in cognitive impairment [168]
Myocardial infarction No significant effect on streptokinase-inducedhypotension in myocardial infarction patients [169]
Sepsis No significant affect in patients with severe sepsis [170]
Organ failure related to
pancreatitis
No significant amelioration of systemic inflammatory
response syndrome in pancreatitis-induced
organ failure
[171]
Modipafant Asthma No significant effect against chronic asthma [158]
Asthma No significant effect in early or late responsesto allergens [172]
Responses to inhaled PAF
Potent inhibition of airway and neutrophil responses
to PAF with a duration of up to 24 h and a reduction of
secondary eicosanoid production in response to
inhaled PAF
[173]
SR27417A
SR27417A
Asthma Modest inhibitory effects against asthma [174,175],
Ulcerative colitis No evidence of efficacy in the treatment of acuteulcerative colitis [176]
WEB 2086
Asthma No attenuation of early of late allergen-inducedresponses or airway hyperresponsiveness [177]
UVB-induced dermatitis Significant inhibition of UVB light-induced erythema [178]
BN 50730 Rheumatoid arthritis Ineffective in the treatment of rheumatoid arthritis [179]
BN 52021
Pulmonary function in the
early post ischaemic graft
function in clinical lung
transplantation
Improvement of alveoloarterial oxygen difference and
a reduction of PAF levels [180]
Ro 24-238 Psoriasis No significant effects reported [181]
TCV-309 Septic shock
No significant difference in adverse events or mortality.
A substantial reduction of organ dysfunction and
morbidity associated with septic shock was reported
[182]
Levocetirizine Chronic idiopathic urticaria Reduction of urticarial activity score [183]
Rupatadine Chronic idiopathic urticaria Reduction of urticarial activity score but not aseffective as levocetirizine [183,184]
Allergic rhinitis and allergies
Significant effects against both conditions as
demonstrated in the comprehensive review by
Mullol et al.
[185]
Y-24180 Asthma Improvement of bronchial hyperresponsiveness inpatients with asthma [186]
Notably, some molecules exhibit dual antagonistic properties towards PAF and other inflammatory
mediators. For instance, rupatadine is both an antagonist of the PAF-R and the histamine H(1)
receptor [187], whereas LDP-392 can target both PAF and 5-lipoxygenase [188]. Likewise, common
statins targeting CVD [189,190] and antiretrovirals targeting human immunodeficiency virus
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(HIV) [191,192] also exhibit anti-PAF pleiotropic effects. Indeed, various other molecules can inhibit
both PAF and inducible nitric oxide synthase induction (iNOS) [193] or thromboxane synthases [194].
Finally, apart from the various compounds presented in Table 2, research has investigated the use
of various inorganic metal complexes including other structurally related and structurally dissimilar
PAF-R antagonists [141]. The authors recommend the following comprehensive reviews for further
information on various synthetic and inorganic metal complexes with PAF-R antagonistic properties,
their structures, synthesis, and biological effects [116,141,167,185].
4.2. PAF Inhibitors of Natural Origin
Extracts from Ginkgo biloba were some of the first PAF inhibitors of natural origin to be discovered.
Several studies by Pierre Braquet and colleagues demonstrated that one compound in particular, BN
2021, was a highly specific competitive PAF antagonist. Several related ginkgolides also exhibited
inhibitory properties against PAF [195–200]. Indeed, several other researchers at the time discovered
anti-PAF properties in other natural isolates of Chinese medicinal herbs such as phomactin A, kadsurenone,
and various xanthones [201–205]. In fact, the discovery that compounds from garlic bulbs possess anti-PAF
activity stimulated interest in the exploration of natural compounds for anti-PAF activity [139].
By 1996, several molecules had been discovered with PAF-like activity as reviewed by Demopoulos [48].
Further experimentation uncovered that a neutral glycerylether lipid without an acetyl group from pine
pollen exhibited biological activity against PAF [206]. Consequently, it was deduced that other lipid extracts
could potentially inhibit PAF-induced platelet aggregation. This led to a series of studies investigating food
lipid extracts starting around 1993, which initially lead to the discovery of PAF antagonists in the polar lipid
fractions of olive oil [207], honey and wax [208], milk and yoghurt [209], mackerel (Scomber scombrus) [210],
and wine [211] before the turn of the century. These studies deduced that mainly polar lipids such as
glycerophospholipids and glycolipids exhibited potent inhibition against PAF-induced platelet aggregation
through competitive binding to the PAF-R. As this research field developed it was noted that many of the
compounds discovered that exhibited anti-PAF activity were also constituents of foods of the Mediterranean
diet [5,212,213]. Therefore, these constituents may be responsible for the observed beneficial effects of
consuming the Mediterranean diet [5,212,213]. Indeed, later research demonstrated that polar lipid extracts
of olive oil, olive pomace, and fish could also affect many of the PAF metabolic enzymes both in vitro and
in vivo [54,214,215]. These extracts were able to aid in the re-equilibration of PAF levels with beneficial
outcomes against models of chronic inflammation.
Research into the effect of lipids on PAF activity and PAF metabolism is still being explored today in
the pursuit of finding natural ways to prevent the pro-inflammatory signalling of PAF. It is now known
that many foods, beverages, and other natural sources including food industry by-products are rich in
PAF antagonists [142,216]. However, there have been several critical discoveries in vivo that suggest that
PAF inhibitors of natural origin may help prevent diseases such as CVD. In studies in vivo, olive oil, olive
oil polar lipids extracts, and olive oil neutral lipids extracts were administered to rabbits consuming an
atherogenic diet. It was demonstrated that rabbits consuming olive oil or olive oil polar lipid extracts
had more beneficial physiological and biochemical changes as a result of increased plasma levels of
PAF-AH, less oxidation in the plasma, a reduction of atherosclerotic lesion thickness, and retention of
vessel wall elasticity, thus impeding atherosclerosis development [217]. These results were corroborated in
a subsequent study that found that polar lipid extracts of olive oil and olive pomace can impede early
atherosclerosis development through reducing platelet sensitivity to PAF and reducing atherosclerotic
lesion thickness [218]. A later follow-up study in rabbits demonstrated that olive pomace polar lipid
extracts were equipotent to simvastatin in preventing the progression of atherogenesis [219].
It was questioned whether other polar lipid extracts of natural origin could exhibit the same effects.
Therefore, two studies of similar design demonstrated anti-atherogenic effects when rabbits consumed
polar lipids extracted from fish (seabream, Sparus aurata) in a model of hypercholesterolaemia. These studies
demonstrated that fish polar lipids could also reduce platelet aggregation, reduce atherosclerotic lesion
size, and increase HDL levels in rabbits [220] along with modulating PAF metabolism leading to lower
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PAF levels and activity in rabbit blood [215]. Representative optic micrographs (×100) of the aortic wall of
these rabbits are presented in Figure 4. These images demonstrate that rabbits consuming an atherogenic
diet supplemented with fish polar lipids leads to a reduction of atherosclerotic lesion width (b) versus a
control group that consumed only an atherogenic diet (a) [220].
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affect platelet aggregation and metabolism postprandially in humans [43,221]. In people with metabolic
syndrome, co sumption of meals i cluding wild plants of the Mediterranean diet rich in PAF inhibitors
postprandially reduced PAF-induced platelet aggregation [222]. Other results from dietary intervention
studies have shown that the administration of traditional Mediterranean iet meals [223,224] to either
normal volunteers or individu l’s with type II diabetes mellitus (who have a predisposition to CVD)
resulted in the characteristic lower PAF activity in blood (measured as PAF-induced platelet aggregability),
which correlates with inhibition of atherogenesis ccording to experiments [217].
Lik wise, dietary supplements can reduce PAF-induced platelet aggregation and increase PAF
catabolism in healthy humans [225]. These studies collectively in icate that consumption of PAF antagonists
from foods a d nutraceuticals may benefit th consumer by reducing the pro-inflammatory effects of
either through inhibiti n of PAF/PAF-R signalling or by influencing the metabolic enzymes of PAF.
Considering, the potential use of dietary polar lipids for the preve tion of CVD, sev ral recent
studies have discovered PAF antagonists in various fish species and by-products of the fishing industry
including salmon fillet and head, minced boarfish, and herring [226–228], and other foods such as
sheep and goat meat [229], milk nd ferme ted dairy products [230–233], an beer and brewi
by-products [234,235]. Futur research in this area ims to dev lop novel functio al foods and
n traceuticals that inc rporate these bioactive polar lipid extracts for the prevention of CVD and other
inflammation-related diseases. For more ext nsive reviews of the anti-inflammatory and antithromb tic
properties of various food polar lipids the authors suggest the following literature [49,142].
5. Current Trends in Platelet-Activating Factor Research
The latest published research in relation to PAF is vast and traverses a plethora of biological
systems and pathways. The following sections provide a brief overview of some of the most exciting
PAF research. However, the topics discussed are not exclusive and an effort has been made to include
various related fields of research.
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5.1. A Potential Anti-Inflammatory Role of PAF
While the majority of the studies relating to PAF research focus on the pathological consequences
of the PAF/PAF-R pathways, there is some evidence that PAF also has anti-inflammatory effects [8].
A recent study demonstrated that TNF-α promotes intestinal mucosal repair by upregulating the
PAF-R in the intestinal epithelium [7]. Similarly, in some cancers PAF exhibits beneficial effects.
Elevated expression of the PAF-R enhances apoptosis via activation of the NF-κB pathways [236,237]
and through the dual action of the NF-κB pathway in malignancy and apoptosis via the immune
response [106,238]. Loss of the PAF-R in mice beneficially augmented PMA-induced inflammation and
chemically induced carcinogenesis, which seems to indicate that the PAF-R suppresses inflammation
and neoplastic development in response to chemically induced carcinogenesis [239]. It is imperative
for the development of future therapeutics that these potential anti-inflammatory properties of the
PAF/PAF-R pathways are more intensively investigated.
5.2. PAF and Cancer
Research regarding the role of PAF in cancer has led to several interesting discoveries over the
last twenty years. PAF is a critical mediator of many cancers [8]. However, it is becoming clear that
PAF plays a significant role in cancers that are particularly difficult to treat. Melanoma for instance
is characterised as the most dangerous form of skin cancer due to its capacity to rapidly metastasise
as a result of pro-inflammatory signalling that is mediated by PAF/PAF-R [109,240,241]. What has
recently become apparent is that pro-oxidative stressors can suppress host immunity through their
ability to generate oxidised lipids and PAF-R agonists [8,242]. It has been demonstrated that PAF
and PAFLL are generated by skin cells on exposure to UV light, thus contributing to the pathology of
melanoma [243]. Indeed, it seems cruelly ironic that PAF and PAFLL are also generated by tumour
cells in melanoma patients following exposure to radiation treatment [242]. Structural analysis of these
PAF-R agonists revealed that radiation therapy leads to the nonenzymatic production of multiple
oxidised glycerophosphocholines (PAFLL) and PAF itself [242].
Other studies have found similar findings [9], whereby PAFLL are generated by radiotherapy,
and that their action on tumour cells protects them from radiation induced cell death by affecting
macrophages. Such PAFLL molecules stimulate tumour growth through immunosuppression [9].
Therefore, the association of radiotherapy with the PAF-R antagonists represents a promising strategy
for improving the efficacy of radiotherapy [8,9]. Additionally, it has been observed that there is elevated
expression of the PAF-R in cervical cancer patients post-surgery [244]. In the same study it was reported
that higher levels of PAF-R mRNA and protein were expressed by squamous carcinoma cell lines
and cervical cancer-derived cell lines than immortalised keratinocytes. Gamma radiation increased
PAF-R expression and the generation of prostaglandin E2 and PAF-R ligands in these tumour cells.
Inhibition of PAF-R signalling by CV-3938 prior to irradiation led to the inhibition of prostaglandin E2
and an increase of tumour cell death. Furthermore, human carcinoma cells transfected with PAF-R
were more resistant to radiation compared to cells lacking the PAF-R. PAF antagonist CV-3988 inhibited
the production of prostaglandin E2 in irradiated cells transfected with PAF-R. As a consequence, it was
deduced that irradiation of carcinoma cells leads to the synthesis of PAF-R ligands and higher expression
of the PAF-R that protects tumour cells from death, and suggests that a combination of radiotherapy
with PAF-R antagonists could be a promising target for cancer treatment [244]. There are several
studies indicating that PAF-R antagonists could also potentially be used as an adjuvant treatment to
chemotherapy in cancer [115,245,246] or to treat common side effects of chemotherapy [247]. A new
approach in this field is the use of PAF inhibitors such as metal compounds, which may have additional
direct anticancer properties (a combined anti-PAF and anticancer activity), to amplify the effectiveness
of common anticancer treatments [8,141,143].
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5.3. Current Research Trends on PAF and PAFLL in Cardiovascular Disease
One of the most topical debates in PAF-related research currently is the role of PAF metabolism
in CVD. PAF biosynthesis, and transport is a tightly regulated process by which enzymatic reactions
involving intracellular and extracellular PAF-AHs terminate signals in the PAF signalling cascade by
selectively degrading PAF and PAFLL [3,12]. There is considerable debate about PAF-AH or the plasma
form lipoprotein-associated phospholipase A2 (Lp-PLA2) and their role in in the development of
atherosclerosis [65]. PAF-AH is a catabolic enzyme of PAF and thus has an anti-inflammatory function.
However, HDL-associated PAF-AHs is thought to be anti-inflammatory and antiatherogenic by its
reduction of monocyte adhesion to the endothelium, its capacity to attenuate phospholipid oxidation,
and its ability to impede the biological activity of minimally modified LDL [105]. On the other hand,
LDL-associated PAF-AH is considered pro-inflammatory and its role in atherosclerosis is controversial.
Functionally, PAF-AHs hydrolyse glycerophospholipids at the sn-2 position, with no preference
for the type of linkage present at the sn-1 position (acyl or alkyl). Hydrolysis of glycerophospholipids
by PAF-AH generates lyso-PAF or lysophosphatidylcholine (lyso-PC) and short or oxidised fatty acids,
many of which tend to exhibit pro-inflammatory properties [248]. This led some researchers to consider
that PAF-AH may contribute to vascular inflammation due to the generation of these pro-inflammatory
molecules [64,65]. As a result, there was a realisation that inhibition of PAF-AH could prevent vascular
inflammation [249]. This in turn led to the development of several PAF-AH inhibitors, including
darapladib that has been tested in clinical trials as an adjunct treatment to cholesterol-lowering therapies
for its capacity to stabilise atherogenic plaques [250–252]. These studies and others in vitro, in vivo,
and in humans have had varying success and it is postulated that darapladib may exert pleiotropic
effects, these findings and more have been extensively reviewed [64,65,248]. It is also hypothesised
that another future strategy to inhibit PAF-AH could involve RNA interference (RNAi), which was
shown to ameliorate atherosclerosis in apolipoprotein E-deficient mice [253,254]. All things considered
the debate surrounding the role of PAF-AH in CVD continues to develop.
On another topical issue, over the past two decades there has been significant breakthroughs in
the understanding of the role of oxidised phospholipids (oxPL) and PAFLL in CVD. Lipid oxidation
products such as oxPL, many of which resemble PAFLL, play a role in various normal and pathological
states [255]. The oxPL acquire different biological activities uncharacteristic of their unoxidised
precursors [256]. For instance, oxPL play a role in angiogenesis, endothelial barrier function, regulation
of innate and adaptive immunity, and thrombosis [255,257]. However, oxPL are more well-known for
their role as inducers of systemic inflammation and atherosclerosis [105,258]. Indeed, bioactive lipids
including PAF, PAFLL, oxPL, and lyso-PC are even present in atherosclerotic plaque [259]. PAF-AH
degrades pro-inflammatory oxPL and plays a key role in the generation of lyso-PC and oxidised fatty
acids [105]. In addition to their pro-inflammatory actions, oxPL can promote anti-inflammatory and
tissue-protective mechanisms, depending on the biological situation [258,260].
OxPL carry out their functions by binding to pattern-recognition receptors (PRR) that are found
on the cell surface [261]. These include toll-like receptors (TLR) and scavenger receptors. OxPL can
also circulate in the blood stream interacting with C-reactive protein (CRP) [262], lipopolysaccharide
binding protein (LPB), or plasma CD14 [260]. Some oxPL can interact with the PAF-R and induce
platelet activation [263]. Current research trends in this field are still interested in discerning the
pro-inflammatory nature of oxPL. However, there is also significant interest in the anti-inflammatory
actions of oxPL, which function by inhibiting inflammatory signalling pathways via NRF2-dependent
and -independent mechanisms, upregulation of genes associated with endogenous antioxidants,
antagonism of TLR and a host of other mechanisms as reviewed by Mauerhofer et al. [264]. In addition,
PAF and PAFLL carry out their functions by binding to TLR, who’s signalling is associated with the
signalling of new PAF production. On the other hand, the PAF receptor appears to also mediate
signalling in the pathogenesis of inflammatory diseases through other molecules outside of PAF
and PAFLL such as lipoteichoic acid (LTA) and various lipopolysaccharides (LPS). This is reviewed
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by Detopoulou et al. [213] who discuss the role of PAF and TLR in the crosstalk of dyslipidaemia,
inflammation, and atherogenesis.
Other research trends are focused on detecting and quantifying the levels of oxPL and PAFLL in
models of disease, the plasma of diseased patients or patients receiving treatments. For instance, the mass
spectrometry analysis of plasma oxPL in diabetes patients [265], the level of plasma oxPL in Alzheimer’s
disease patients treated with a carotenoid supplement [266], or PAFLL in coronary artery disease patients at
risk of cognitive decline due to depression [267]. However, one of the current major challenges of oxPL, PAF,
and PAFLL research is the development of simplified mass spectrometric procedures for high-throughput
and affordable analysis [268,269]. Certainly, there are several limitations to PAF quantification including
sensitivity, pre-analysis derivatization, interference with isobaric molecules, and the fact that it is expensive
to conduct [269]. Therefore, further research is required to develop reliable, inexpensive, and reproducible
methods to further advance this research field.
5.4. Current Research Trends on PAF in Neurological Disorders
PAF also seems to be involved in the development of CNS disorders. The latest research indicates
that PAF alters blood–brain barrier permeability, which may have implications for CNS inflammatory
disorders [270]. Indeed, PAF may be implicated in the development of cerebral dysfunction following
traumatic brain injuries [271] and PAF-R mediated signalling may affect postsynaptic hippocampal
injury in encephalomyelitis [272]. PAF also seems to be involved in neurodegenerative diseases such
as amyotrophic lateral sclerosis [273]. There is evidence that PAF is critical to inflammatory signalling
in pain, spinal cord injury, and traumatic brain injury itself [274–276]. Finally, as PAF is a mediator of
various neurodegenerative diseases it is imperative to understand PAF-mediated cell signalling and its
inhibition. For instance, in the early stages of Alzheimer’s disease, cognitive decline and synapse loss
seem to be inhibited by ginkgolides A and B, which are PAF-R antagonists [277]. Likewise, several
studies have suggested that PAF-R antagonists may be beneficial in the treatment of Parkinson’s
disease and prion-induced synapse degradation [117,278,279].
In relation to neurological issues, early studies indicated that injecting PAF into peripheral tissues
such as skin enhanced pain sensitivity in animals and humans [276,280]. Notably, there are now several
studies implicating PAF in pain signalling due to the role of PAF in regulating various functions of cells
in the peripheral tissues and the CNS [276]. As such, the PAF/PAF-R signalling cascade seems to be
involved in tissue injury-induced pain and neuropathic pain [276]. Indeed, there is some evidence to
suggest that PAF antagonists may be anti-allodynic [281]. Animals studies have also shown that PAF
antagonists (TCV-309) alone or in combination with opioids reduced pain in animal models of bone
cancer pain indicating that they may have palliative properties [282]. Recently it has been determined
that lysophosphatidylcholine acyltransferase (LPCAT)2 along with PAF antagonists (ABT-491) may be
a novel therapeutic target for analgesic drugs due to the fact that it’s deficiency in partial sciatic nerve
ligation seemed to attenuate pain in mice [283].
5.5. Current Research Trends on PAF in Renal and Urinary System Disorders
The role of PAF in renal function and pathology dates back to when the structure of PAF was
first being determined. Snyder and colleagues described a molecule they termed APRL, which was
later identified as being PAF. In renal physiology, PAF is considered one of the main inflammatory
mediators [284]. PAF is synthesised in the kidney by various renal cells including mesangial cells but
is also present due to infiltrating inflammatory cells [54,285]. PAF does not accumulate in the renal
cells, but it is secreted and affects mesangial cells, neighbouring podocytes, and other infiltrating cells
by binding to the PAF-R and inducing its signalling pathways [5]. Excessive production of PAF can
lead to damage of these cells, thus inducing glomerulosclerosis and proteinuria [132]. PAF may also
play a role in renal haemodynamics [286]. PAF antagonists have exhibited promising results in renal
disorders [132] and components of the Mediterranean diet seem to exhibit effects on PAF metabolism
in relation to the renal system [54,214]. Notably, vitamin D and its analogue paricalcitol exhibited
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strong anti-PAF effects in human cells. Administration of paricalcitol in haemodialysis patients for
one month reduced PAF synthesis and increased PAF catabolism, which was accompanied with a
reduction of PAF levels, renal inflammation [56]. However, further research is required in this field to
fully understand how PAF/PAF-R signalling affects renal pathophysiology to develop novel treatments
for glomerulosclerosis and proteinuria.
Interestingly the kidneys are not the only organ in the renal system affected by PAF and its
metabolism. In humans, it is thought that cigarette smoking leads to alterations in urethral cells that
share similar histology to urethral cells of interstitial cystitis and bladder pain syndrome (IC/BPS)
patients through an inflammatory pathway mediated by PAF [287]. Overall it is demonstrated that
PAF signalling is upregulated in IC/BPS and that cigarette smoke exposure further upregulated this
pathway [287]. Future research aims to determine the role of PAF in IC/BPS development, whether
PAF can act as a marker of IC/BPS, and if PAF antagonists may have therapeutic value in IC/BPS [288].
Likewise, PAF seems to be implicated in the development of bladder cancer [287]. This is unsurprising
as several lines of research indicate that smoking cigarettes seem to induce the generation of PAF and
PAFLL in other cancer pathologies including breast cancer [289,290]. What is most significant about the
series of studies relating to cigarette smoke is that it is clear that PAF activity and metabolism is directly
affected by lifestyle choices. Worryingly, in relation to the latest trend of consuming E-cigarettes,
PAF-R expression is increased following their use, which may increase one’s risk of pneumococcal
infections [291]. This may have untold health consequences to E-cigarette users over time. On a positive
note, current research interests seem to be trending towards determining the role of lifestyle factors
such as the use of E-cigarettes and other environmental stressors on PAF activity and metabolism [46].
6. New Frontiers in PAF Research
Over the last two years there have been remarkable discoveries concerning the PAF/PAF-R
relationship. Indeed, the PAF-R structure has been elucidated and there is evidence that PAF
induced signal transduction independent of the PAF-R as elaborated further in Sections 6.1 and 6.2.
These discoveries will open the PAF research field to new possibilities and greater understanding of
the pathophysiological roles and functions of PAF and its receptor.
6.1. PAF-R Strucutral Elucidation
One of the most significant recent achievements in PAF research has been the elucidation of the
structure of the PAF-R. Previous research was unable to determine the structure of human PAF-R.
Instead, bovine rhodopsin was used as a model of the PAF-R [164]. Cao, Tan, Zhang, Wu, and colleagues
recently solved the crystal structures of human PAF-R in complex with a PAF antagonist SR 27,417 and
a PAF inverse agonist ABT-491 [292]. This is extremely important for GPCR research as only seven
other lipid receptor structures have been elucidated [293,294]. Gaining a greater understanding of the
PAF-R structure and its capacity to bind various ligands will allow for the development of effective
therapeutic strategies against the PAF/PAF-R pathways. Moreover, this research will pave the way for
the elucidation of other GPCR structures that are critical in physiology and pathophysiology.
6.2. Induction of Inflammatory Pathways Independent of the PAF-R
Finally, the majority of the pro-inflammatory effects of PAF are due to PAF binding to the
PAF-R. However, recently it has been discovered that PAF can mediate NLRP3 (nucleotide-binding
oligomerization domain, leucine-rich repeat–containing receptor family pyrin domain-containing
3)-NEK7 (NIMA-related kinase 7) inflammasome induction independently of the PAF-R [295].
Notably, PAF and PAFLL can activate the inflammasome resulting in IL-18 and IL-1β maturation,
which is dependent on NLRP3, ASC (apoptosis-associated speck like protein containing a caspase
recruitment domain), caspase-1, potassium efflux, and calcium influx. These findings are significant
as they may explain why despite promising data, PAF antagonists have previously failed to exhibit
clinical benefit in clinical trials relating to PAF-mediated inflammation in sepsis, acute pancreatitis,
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and asthma [171,296–298]. Additionally, the PAF-R modulates colitis-induced pulmonary inflammation
through the NLRP3 inflammasome [299]. Considering the link between PAF/PAF-R and activation
of the NLRP3 inflammasome, further research is required to discern whether PAF also activates the
NLRP3 inflammasome in atherosclerosis [300].
7. Conclusions and Future Research Perspectives
It is clear that the discovery and structural elucidation of PAF sparked major interest into the
role of PAF in physiology and pathophysiology, along with lipid mediators in general from the 1970s
onwards. When the role of PAF in various diseases became clear researchers began to search for
and design molecules to inhibit the actions of PAF. The aim of this article was to try present an
overall picture of some of the historical perspectives and current research trends in relation to PAF
research. It is clear from the wealth of evidence presented that understanding the mechanisms of
PAF/PAF-R signalling in health and disease has yet to be fully elucidated. However, the discovery of
various PAF and PAFLL agonists and antagonists, the role of the PAF metabolic enzymes in diseases,
solving the human PAF-R structure, and identifying PAF signalling mechanisms independent of the
PAF-R are some of the many major achievements in current PAF research. Nevertheless, despite all
of these achievements, clinical trials have failed to demonstrate the efficacy of PAF-R antagonists in
the treatment of inflammatory diseases. Similarly, lipidomic research has yet to provide a reliable,
reproducible, and inexpensive method of PAF and PAFLL identification and quantification to be used
as a biomarker of inflammatory diseases. These are just some of the many challenges that exist in PAF
research. The importance to research PAF and its related signalling processes lies in the fact that it
is involved in so many inflammation-related diseases, particularly CVD. However, as per Section 6,
there have been critical breakthroughs in PAF research that hold significant promise in this research
field. Future PAF research will most likely target PAF in conjunction with various other inflammatory
mediators for novel multi-modal therapeutics. Therefore, it is clear that there is an abundance of
research yet to be conducted to fully understand the mechanisms induced and governed by PAF and
its metabolism in physiology and pathophysiology.
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